Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CXCR6 | O00574 | 13/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669624 | 0.90 | PTGS2 (0.59) | POLBPTGS2MAPTKDM4ELMNA | |
| SCHEMBL6669630 | 0.90 | PTGS2 (0.59) | POLBPTGS2MAPTKDM4ELMNA | |
| SCHEMBL6644347 | 0.86 | PTGS2 (0.61) | POLBPTGS2MAPTKDM4ELMNA | |
| SCHEMBL6639409 | 0.86 | PTGS2 (0.61) | POLBPTGS2MAPTKDM4ELMNA | |
| SCHEMBL6642320 | 0.82 | MAPT (0.43) | POLBMAPT | |
| SCHEMBL6639081 | 0.82 | POLB (0.46) | POLBPTGS2MAPTKDM4ELMNA | |
| SCHEMBL6801757 | 0.77 | MAPT (0.45) | POLBMAPTKDM4E | |
| SCHEMBL6644456 | 0.77 | ACACB (0.40) | POLBMAPTLMNA | |
| SCHEMBL6638957 | 0.75 | KMT2A (0.42) | POLBKDM4ELMNA | |
| SCHEMBL6774056 | 0.75 | KMT2A (0.42) | POLBKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | POLB 2053/4885PTGS2 822/4885CXCR6 2250/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | POLB 2045/4885PTGS2 877/4885CXCR6 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.